mohamed haddad

Dr. mohamed haddad


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
MHmohamed haddad
mohamed haddad
VHVincent Hervé
Vincent Hervé
MKMohamed Raâfet Ben Khedher
Mohamed Raâfet Ben Khedher
JRJean-Michel Rabanel
Jean-Michel Rabanel
CRCharles Ramassamy
Charles Ramassamy
Significance: Glutathione (GSH) represents the most abundant and the main antioxidant in the body with important functions in the brain related to Alzheimer’s disease (AD). Recent Advances: Oxidative stress is one of the central mechanisms in AD. We and others have demonstrated the alteration of GSH in AD brain, its important role for the detoxification of advanced glycation end products and of acrolein. Recent in vivo studies found a decrease of GSH in different area of the brain from control, mild cognitive impairment and AD subjects which is correlated with cognitive functions. Critical Issues: Several strategies were developed to restore its intracellular level with the L-cysteine prodrugs or the oral administration of γ-glutamylcysteine (γ-GC) to prevent alterations observed in AD. To date, no benefit on GSH levels or oxidation biomarkers have been reported in clinical trials. Thus, it remains uncertain if GSH could be considered as a potential preventive or therapeutic approach or as a biomarker for AD. Future Directions: We will address how GSH-coupled nanocarriers represent a promising approach for the functionalization of nanocarriers to overcome the blood brain barriers (BBB) for the delivery of GSH to the brain while avoiding cellular toxicity. It is also important to address the presence of GSH in exosomes for its potential intercellular transfer or to cross the BBB under certain conditions.

Verified
Journal Article
Open access
PDF file
MHmohamed haddad
mohamed haddad
MPMorgane Perrotte
Morgane Perrotte
MKMohamed Raâfet Ben Khedher
Mohamed Raâfet Ben Khedher
CDClément Demongin
Clément Demongin
ALAurélie Lepage
Aurélie Lepage
CRCharles Ramassamy
Charles Ramassamy
Methylglyoxal (MG) and glyoxal (GO) are suggested to be associated with the development of neurodegenerative pathologies. However, their peripheral levels in relation to cognitive decline and their effects on key factors in neuronal cells are poorly investigated. The aim of this study was to determine their serum levels in MCI (mild cognitive impairment) and Alzheimer’s disease (AD) patients, to analyze their effects on the neurotrophic and inflammatory factors, on neurodegenerative markers in neuronal cells and in neuronal derived-extracellular vesicles (nEVs). Our results show that MG and GO levels in serum, determined by HPLC, were higher in MCI. ROC (receiver-operating characteristic curves) analysis showed that the levels of MG in serum have higher sensitivity to differentiate MCI from controls but not from AD. Meanwhile, serum GO levels differentiate MCI from control and AD groups. Cells and nEVs levels of BDNF, PRGN, NSE, APP, MMP-9, ANGPTL-4, LCN2, PTX2, S100B, RAGE, Aβ peptide, pTau T181 and alpha-synuclein were quantified by luminex assay. Treatment of neuronal cells with MG or GO reduced the cellular levels of NSE, PRGN, APP, MMP-9 and ANGPTL-4 and the nEVs levels of BDNF, PRGN and LCN2. Our findings suggest that targeting MG and GO may be a promising therapeutic strategy to prevent or delay the progression of AD.